Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Date:4/27/2011

TARRYTOWN, N.Y. and BERLIN, April 27, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO).  The positive results from the GALILEO study confirm the results of the similarly designed Phase 3 COPERNICUS study that were announced in December 2010.

In GALILEO, the primary endpoint at week 24 was achieved: 60.2 percent of patients receiving monthly VEGF Trap-Eye 2 milligrams (mg) gained at least 15 letters of vision from baseline, compared to 22.1 percent of patients receiving sham injections (p<0.0001).  The key secondary endpoint of the study was also met: patients receiving VEGF Trap-Eye 2mg monthly gained, on average, 18 letters of vision compared to a mean gain of 3.3 letters with sham injections (p<0.0001).

"After reporting positive results from the VIEW 1 and VIEW 2 Phase 3 studies for the treatment of the neovascular form of age-related macular degeneration, or wet AMD, we are very pleased to now also have two positive Phase 3 trials with VEGF Trap-Eye in central retinal vein occlusion," said Kemal Malik, M.D., Head of Global Development and member of the Bayer HealthCare Executive Committee.

"With two Phase 3 trials showing impressive improvement in vision relative to control, VEGF Trap-Eye has the potential to provide patients and physicians a new treatment option for central retinal vein occlusion," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories.

As in the COPERNICUS trial, VEGF Trap-Eye was generally well tolerated in the GALILEO study and the most common adverse events were those typically associated with intravitreal injections or the underlying
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
2. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
4. Regeneron Announces March 2011 Investor Conference Presentations
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
7. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
8. Regeneron Announces Presentation at the ISI Annual Conference
9. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
10. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
11. Christine A. Poon Elected to Regeneron Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
(Date:1/14/2014)... NuAire , a manufacturer of ergonomically designed laboratory equipment ... of Japan to sell and service the ... NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and features, options ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Texas, May 22, 2012  Prodigy Generics, a division of ... Irinotecan is the generic equivalent of the branded drug ... Pharmaceutical Laboratories to develop a portfolio of oncology products. ... through the partnership that will add consistent supply and ...
... May 22, 2012  MusclePharm Corporation (OTCBB: MSLP.OB), a nutritional ... it has signed Major League Baseball phenom Bryce Harper ... disclosed. Harper, a 19-year-old star outfielder for ... April 28.  He previously was the Number 1 overall ...
Cached Medicine Technology:MusclePharm Signs Pro Baseball Rookie Phenom Bryce Harper As Sponsored Athlete 2
(Date:4/18/2014)... medical-testing device is being prepped to enter the ... diagnosis of certain diseases in remote areas, thanks ... of investigations aboard the International Space Station on ... space-tested concept of capillary flow to diagnose infectious ... Kelso, Ph.D., a researcher at Northwestern University in ...
(Date:4/18/2014)... What,s one of your worst memories? How did it ... felt during a negative personal experience, such as how ... lead to emotional distress, especially when you can,t stop ... creep up, thinking about the context of the memories, ... and effective way to alleviate the negative effects of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... In the April issue of Experimental Biology ... by Drs. Rex Gaskins and Paul Kenis in ... campus of the University of Illinois Urbana-Champaign describe ... reduction-oxidation reactions underlie a variety of cell functions ... to these crucial roles in regulating normal cellular ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... Solta Medical, Inc. (Nasdaq: SLTM ), ... announced that it has received regulatory clearance to market ... excited about the opportunity to market the premier non-invasive ... Republic of China," said Stephen J. Fanning, Chairman of ...
... ProMetic Life Sciences Inc. (TSX: PLI ... announces that it has retained the services of ... subsidiaries of Sumitomo Corporation ("Sumitomo") to advise ProMetic in ... Japanese market.In the course of ProMetic,s partnering activities several ...
... that can cause anal and cervical cancers, is associated with ... men who have sex with men (MSM), according to new ... journal AIDS , the findings are available now. ... , In previous studies, other sexually transmitted infections have been ...
... Wolff today assured Pennsylvanians that the 2009 H1N1 influenza strain ... anywhere in either the U.S. or Mexico, and that pork ... as the ,swine flu, many misconceptions relating to pigs have ... and living near or working on a hog farm is ...
... 30 The Alzheimer,s Association Minnesota-North Dakota in collaboration ... segment of The Alzheimer,s Project on May 12 at ... screening will be followed by a question-and-answer panel of ... for the disease, The Alzheimer,s Project shows there is ...
... Exforge HCT combines a proven calcium channel blocker, ... in one pill - In a clinical trial, ... and diastolic BP, compared to all dual combinations ... patients may need multiple medications to help control ...
Cached Medicine News:Health News:Solta Medical Receives Regulatory Approval to Market Thermage Systems in China 2Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 2Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 3Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 4Health News:Cancer-causing virus associated with higher risk of new HIV infection 2Health News:Pennsylvania Pork Products Safe During H1N1 Flu Outbreak, Says Ag Secretary 2Health News:The Alzheimer's Project HBO Documentary Puts Spotlight On Alzheimer's Disease; Premiere Screening at the Hennepin County Library in Downtown Minneapolis 2Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 2Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 4Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 5Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 6Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 7
Platinum General Purpose Cautery Electrodes , ,A - Loop Tip, ,Fully autoclavable. Tips typically last for 50 to 100 or more procedures, depending on burn time....
Non-Cantilevered, "Teardrop" Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring ovoid approximately 6.0 mm in diameter....
... Customized stethoscope earmolds add comfort and ... such as ambulance paramedics, Flight-for-Life helicopter personnel, ... ,These molds are specific in design and ... any stethoscope used in today's industry to ...
... Bispectral Index (BIS®) measurement uses Aspect Medical ... of consciousness and sedation monitoring for use ... settings., ,The plug-and-play BISx Power Link™ ... integrated clamp for quick and easy mounting ...
Medicine Products: